
Baxter International (BAX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
2.6B
Gross Profit
861.0M
32.80%
Operating Income
58.0M
2.21%
Net Income
126.0M
4.80%
EPS (Diluted)
$0.25
Balance Sheet Metrics
Total Assets
21.3B
Total Liabilities
14.2B
Shareholders Equity
7.1B
Debt to Equity
2.02
Cash Flow Metrics
Operating Cash Flow
54.0M
Free Cash Flow
-315.0M
Revenue & Profitability Trend
Baxter International Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 10.6B | 14.8B | 14.5B | 12.1B | 11.7B |
Cost of Goods Sold | 6.7B | 9.8B | 9.4B | 7.4B | 7.1B |
Gross Profit | 4.0B | 5.0B | 5.1B | 4.7B | 4.6B |
Gross Margin % | 37.5% | 33.6% | 34.9% | 38.9% | 39.3% |
Operating Expenses | |||||
Research & Development | 590.0M | 667.0M | 602.0M | 531.0M | 521.0M |
Selling, General & Administrative | 3.0B | 3.9B | 3.9B | 2.8B | 2.5B |
Other Operating Expenses | -12.0M | - | - | - | - |
Total Operating Expenses | 3.5B | 4.6B | 4.5B | 3.4B | 3.0B |
Operating Income | 439.0M | 370.0M | 605.0M | 1.3B | 1.6B |
Operating Margin % | 4.1% | 2.5% | 4.2% | 11.1% | 13.7% |
Non-Operating Items | |||||
Interest Income | 67.0M | 70.0M | 20.0M | 14.0M | 19.0M |
Interest Expense | 408.0M | 512.0M | 415.0M | 207.0M | 153.0M |
Other Non-Operating Income | -387.0M | -32.0M | -2.9B | -35.0M | -171.0M |
Pre-tax Income | -289.0M | -103.0M | -2.6B | 1.1B | 1.3B |
Income Tax | 37.0M | -34.0M | 4.0M | 83.0M | 182.0M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 7.4% | 14.1% |
Net Income | -638.0M | 2.7B | -2.4B | 1.3B | 1.1B |
Net Margin % | -6.0% | 18.0% | -16.7% | 10.7% | 9.5% |
Key Metrics | |||||
EBITDA | 1.6B | 1.8B | 2.0B | 2.2B | 2.4B |
EPS (Basic) | $-1.27 | $5.25 | $-4.83 | $2.56 | $2.17 |
EPS (Diluted) | $-1.27 | $5.25 | $-4.83 | $2.53 | $2.13 |
Basic Shares Outstanding | 510000000 | 506000000 | 504000000 | 502000000 | 509000000 |
Diluted Shares Outstanding | 510000000 | 506000000 | 504000000 | 502000000 | 509000000 |
Income Statement Trend
Baxter International Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.8B | 3.2B | 1.7B | 3.0B | 3.7B |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.7B | 2.7B | 2.6B | 2.6B | 2.0B |
Inventory | 2.0B | 2.8B | 2.7B | 2.5B | 1.9B |
Other Current Assets | 328.0M | 387.0M | 368.0M | 390.0M | 342.0M |
Total Current Assets | 8.9B | 9.6B | 8.0B | 8.9B | 8.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 773.0M | 2.2B | 2.2B | 2.3B | 2.3B |
Goodwill | 15.8B | 19.1B | 19.7B | 27.5B | 8.1B |
Intangible Assets | 5.2B | 6.1B | 6.8B | 7.8B | 1.7B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 3.1B | 803.0M | 1.4B | 790.0M | 1.1B |
Total Non-Current Assets | 16.9B | 18.7B | 20.3B | 24.6B | 11.6B |
Total Assets | 25.8B | 28.3B | 28.3B | 33.5B | 20.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 968.0M | 1.2B | 1.1B | 1.2B | 1.0B |
Short-term Debt | 2.8B | 2.8B | 1.5B | 639.0M | 517.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 1.0B | 110.0M | 161.0M | 97.0M | 92.0M |
Total Current Liabilities | 6.5B | 6.5B | 4.7B | 4.2B | 3.3B |
Non-Current Liabilities | |||||
Long-term Debt | 10.6B | 11.6B | 15.7B | 17.7B | 6.3B |
Deferred Tax Liabilities | 103.0M | 447.0M | 661.0M | 962.0M | 143.0M |
Other Non-Current Liabilities | 132.0M | 178.0M | 217.0M | 287.0M | 169.0M |
Total Non-Current Liabilities | 12.2B | 13.3B | 17.6B | 20.2B | 8.0B |
Total Liabilities | 18.8B | 19.8B | 22.4B | 24.4B | 11.3B |
Equity | |||||
Common Stock | 683.0M | 683.0M | 683.0M | 683.0M | 683.0M |
Retained Earnings | 14.9B | 16.1B | 14.0B | 17.1B | 16.3B |
Treasury Stock | 11.1B | 11.2B | 11.4B | 11.5B | 11.1B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 7.0B | 8.5B | 5.9B | 9.1B | 8.7B |
Key Metrics | |||||
Total Debt | 13.4B | 14.4B | 17.2B | 18.3B | 6.8B |
Working Capital | 2.3B | 3.1B | 3.3B | 4.6B | 5.1B |
Balance Sheet Composition
Baxter International Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -326.0M | -69.0M | -2.7B | 1.0B | 1.1B |
Depreciation & Amortization | 997.0M | 1.3B | 1.4B | 867.0M | 823.0M |
Stock-Based Compensation | 114.0M | 133.0M | 153.0M | 146.0M | 130.0M |
Working Capital Changes | -155.0M | -104.0M | -671.0M | -229.0M | -321.0M |
Operating Cash Flow | 409.0M | 801.0M | -2.0B | 1.7B | 1.6B |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | - | -6.0M | -263.0M | -10.5B | -494.0M |
Investment Purchases | - | - | - | - | - |
Investment Sales | 34.0M | - | - | - | - |
Investing Cash Flow | 50.0M | 20.0M | -252.0M | -10.5B | -470.0M |
Financing Activities | |||||
Share Repurchases | 0 | 0 | -32.0M | -600.0M | -500.0M |
Dividends Paid | -590.0M | -586.0M | -573.0M | -530.0M | -473.0M |
Debt Issuance | - | 0 | 0 | 11.9B | 1.9B |
Debt Repayment | -2.7B | -2.6B | -954.0M | -2.8B | -1.2B |
Financing Cash Flow | -1.2B | -3.6B | -1.6B | 8.1B | -547.0M |
Free Cash Flow | 559.0M | 1.0B | 591.0M | 1.5B | 1.2B |
Net Change in Cash | -693.0M | -2.8B | -3.9B | -662.0M | 550.0M |
Cash Flow Trend
Baxter International Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
86.31
Forward P/E
8.28
Price to Book
1.67
Price to Sales
1.13
PEG Ratio
-0.67
Profitability Ratios
Profit Margin
-1.42%
Operating Margin
15.45%
Return on Equity
-3.21%
Return on Assets
2.73%
Financial Health
Current Ratio
2.30
Debt to Equity
133.35
Beta
0.58
Per Share Data
EPS (TTM)
$-0.48
Book Value per Share
$14.26
Revenue per Share
$21.28
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
bax | 12.3B | 86.31 | 1.67 | -3.21% | -1.42% | 133.35 |
Intuitive Surgical | 163.3B | 63.00 | 9.08 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 55.7B | 35.46 | 2.18 | 6.18% | 7.41% | 75.93 |
Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
ResMed | 40.8B | 29.26 | 6.83 | 25.86% | 27.22% | 14.27 |
West Pharmaceutical | 19.6B | 40.74 | 6.69 | 17.72% | 16.48% | 10.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.